News | November 14, 2023
Biocon Biologics receives MHRA, UK Approval for Biosimilar Aflibercept ‘Yesafili’
Yesafili, received marketing authorization approval from the European Commission for the European Union
Yesafili, received marketing authorization approval from the European Commission for the European Union
RHTC will address a long-standing healthcare access issue for all the local population
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
Tele-MANAS has counseled more than 3,50,000 people till date and currently provides counseling to 2000 people through 44 Tele Manas Cells
Ayush Minister launched month long ayurveda celebration drive of Ministry of Ayush
The World Homoeopathy Day commemorates the birth anniversary of Dr Samuel Hahnemann on 10th of April
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
Subscribe To Our Newsletter & Stay Updated
